Literature DB >> 22577175

Dynamic antibody-binding properties in the pathogenesis of HIT.

Bruce S Sachais1, Rustem I Litvinov, Serge V Yarovoi, Lubica Rauova, Jillian L Hinds, Ann H Rux, Gowthami M Arepally, Mortimer Poncz, Adam Cuker, John W Weisel, Douglas B Cines.   

Abstract

Rapid laboratory assessment of heparin-induced thrombocytopenia (HIT) is important for disease recognition and management. The utility of contemporary immunoassays to detect antiplatelet factor 4 (PF4)/heparin antibodies is hindered by detection of antibodies unassociated with disease. To begin to distinguish properties of pathogenic anti-PF4/heparin antibodies, we compared isotype-matched monoclonal antibodies that bind to different epitopes: KKO causes thrombocytopenia in an in vivo model of HIT, whereas RTO does not. KKO binding to PF4 and heparin is specifically inhibited by human HIT antibodies that activate platelets, whereas inhibition of RTO binding is not differentially affected. Heparin increased the avidity of KKO binding to PF4 without affecting RTO, but it did not increase total binding or binding to nontetrameric PF4(K50E). Single-molecule forced unbinding demonstrated KKO was 8-fold more reactive toward PF4 tetramers and formed stronger complexes than RTO, but not to PF4(K50E) dimers. KKO, but not RTO, promoted oligomerization of PF4 but not PF4(K50E). This study reveals differences in the properties of anti-PF4 antibodies that cause thrombocytopenia not revealed by ELISA that correlate with oligomerization of PF4 and sustained high-avidity interactions that may simulate transient antibody-antigen interactions in vivo. These differences suggest the potential importance of epitope specificity in the pathogenesis of HIT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577175      PMCID: PMC3412334          DOI: 10.1182/blood-2012-01-407262

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

2.  Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets.

Authors:  B H Chong; I Fawaz; C N Chesterman; M C Berndt
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

3.  Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.

Authors:  J I Zwicker; L Uhl; W-Y Huang; B H Shaz; K A Bauer
Journal:  J Thromb Haemost       Date:  2004-12       Impact factor: 5.824

4.  Dynamic strength of molecular adhesion bonds.

Authors:  E Evans; K Ritchie
Journal:  Biophys J       Date:  1997-04       Impact factor: 4.033

5.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

6.  Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.

Authors:  T L Bauer; G Arepally; B A Konkle; B Mestichelli; S S Shapiro; D B Cines; M Poncz; S McNulty; J Amiral; W W Hauck; R N Edie; J D Mannion
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

7.  Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia.

Authors:  C Pouplard; J Amiral; J Y Borg; S Laporte-Simitsidis; B Delahousse; Y Gruel
Journal:  Am J Clin Pathol       Date:  1999-05       Impact factor: 2.493

8.  Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein.

Authors:  K S Park; S Rifat; H Eck; K Adachi; S Surrey; M Poncz
Journal:  Blood       Date:  1990-03-15       Impact factor: 22.113

9.  Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Authors:  L Ziporen; Z Q Li; K S Park; P Sabnekar; W Y Liu; G Arepally; Y Shoenfeld; T Kieber-Emmons; D B Cines; M Poncz
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  25 in total

1.  Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies.

Authors:  Thi-Huong Nguyen; Andreas Greinacher
Journal:  Eur Biophys J       Date:  2017-07-15       Impact factor: 1.733

2.  Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients.

Authors:  Chezi Ganzel; Jacob Rowe; David Raveh
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

3.  Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Authors:  Kandace Gollomp; Minna Kim; Ian Johnston; Vincent Hayes; John Welsh; Gowthami M Arepally; Mark Kahn; Michele P Lambert; Adam Cuker; Douglas B Cines; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  JCI Insight       Date:  2018-09-20

4.  Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.

Authors:  Valerie Tutwiler; Daria Madeeva; Hyun Sook Ahn; Izabella Andrianova; Vincent Hayes; X Long Zheng; Douglas B Cines; Steven E McKenzie; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2015-10-30       Impact factor: 22.113

5.  Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

Authors:  Rustem I Litvinov; Serge V Yarovoi; Lubica Rauova; Valeri Barsegov; Bruce S Sachais; Ann H Rux; Jillian L Hinds; Gowthami M Arepally; Douglas B Cines; John W Weisel
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

6.  Novel diagnostic assays for heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Ann H Rux; Jillian L Hinds; May Dela Cruz; Serge V Yarovoi; Isola A M Brown; Wei Yang; Barbara A Konkle; Gowthami M Arepally; Stephen P Watson; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

Review 7.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 8.  Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Authors:  Zheng Cai; Zhiqiang Zhu; Mark I Greene; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

9.  Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Authors:  Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

Review 10.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.